



AG Medizinische Statistik Prof. Dr. Martin Hellmich

Statistical Analysis Plan

Study title: Early oral switch therapy in low-risk staphylococcus aureus

bloodstream infection

Study code: SABATO

Study design: Multicenter, multinational clinical trial, two arms, randomized,

open-label, non-inferiority, parallel-group

Indication: Staphylococcus aureus bloodstream infection

Investigational intervention: Orally administered antimicrobial – Oral switch therapy (OST)

Comparator: Intravenously administered antimicrobial – Intravenous standard

therapy (IST)

Sponsor (or representative): Heinrich-Heine-Universität Düsseldorf

Universitätsstr. 1 40225 Düsseldorf

Germany

represented by the principal investigator

Financial support: Deutsche Forschungsgemeinschaft (DFG, German Research

Foundation; grant number KA 3104/2-1 and KA 3104/2-2)

Protocol identification: Uni-Koeln-1400

Principal Coordinating

Prof. Dr. Achim Kaasch

investigator:

Institute of Medical Microbiology and Hospital Hygiene

Düsseldorf University Hospital

Universitätsstr. 1 40225 Düsseldorf

Germany

Statistics: Institute of Medical Statistics and Computational Biology (IMSB)

Kerpener Str. 62 50937 Cologne

Germany

SAP author: Anne Adams (IMSB)

CONFIDENTIAL

SAP version: V02 final Date: 15.04.2021

Approved by

Prof. Dr. Achim Kaasch Principal Investigator

21.04.2021

Signature

Prof. Dr. Martin Hellmich

Statistician

22.04.2021

Date

Date

Signature

Anne Adams, MSc

Statistician

15.04.2021

Date

Signature

Content

1	Bac	kground	4
	1.1	Trial objective	
	1.2	Trial design	4
	1.3	Timing of analyses	6
	1.4	Sample size	6
2	Ana	lysis populations	7
	2.1	Definitions	7
	2.2	Major protocol violations / Withdrawals	8
3	Tria	centres	8
4	Ana	lysis variables	11
	4.1	Demography and baseline characteristics	11
	4.2	Primary variable	11
	4.3	Secondary variables	12
5	Han	dling of missing values and outliers	13
	5.1	Missing values	13
	5.2	Outliers	
6	Stat	istical analyses / methods	
	6.1	Patient disposition	
	6.2	Demography and baseline characteristics	
	6.3	Primary analysis	
	6.4	Secondary analyses	
	6.5	Safety	
	6.6	Subgroup analyses	
	6.7	Additional Analysis	
	6.8	Interim analysis	
7		a problems	
8		ware	
9		erences	
1(endices	
	10.1	List of abbreviations	
	10.2	List of variables for demography	12

1 Background

1.1 Trial objective

The primary objective of this trial is to demonstrate that in patients with low-risk *S. aureus* bloodstream infection (SAB) a switch from intravenous to oral antimicrobial therapy (oral switch therapy, OST) is non-inferior to a conventional course of intravenous therapy (intravenous standard therapy, IST). This will be achieved by comparing the rate of SAB-related complications (relapsing SAB, deep-seated infection with *S. aureus*, or mortality attributable to SAB) within 90 days. Low-risk SAB manifests itself typically in patients with comorbidities. Therefore, survival is largely determined by the underlying disease and was not chosen as a primary endpoint. However, death related to SAB is included in the primary endpoint. Death unrelated to SAB will be carefully evaluated and compared.


The secondary objective is to measure the potential benefit for the patient. This is achieved by evaluating the length of hospital stay after the first positive blood culture and complications of intravenous therapy. A considerable number of patients on OST are expected to be discharged earlier from hospital, since hospital stay due to intravenous therapy is no longer required. This will reduce the risks associated with hospitalization and i.v. therapy (catheter-related infection, venous thrombosis, and septic thrombophlebitis) and is likely to improve patients' quality of life.

1.2 Trial design

The study is a Phase III, multicentre, open-label, randomized, controlled, non-inferiority trial to test whether a switch form intravenous to oral antimicrobial therapy (oral switch therapy, OST) is non-inferior to a conventional course of intravenous therapy (intravenous standard therapy, IST) in patients with SAB. The clinical trial will be carried out as a multicentre open trial at trial sites in Germany, the Netherlands, France, and Spain.

Patients are randomly allocated to treatment arms (1:1) not earlier than one day before starting study drug. This is achieved by a central 24-7 Internet randomization service ALEA (stratified by study center, permuted blocks of varying length). Authorized local study staff may login to a secure website, randomize a patient and receive an email with attached pdf giving all the details on the allocated treatment. The randomization service is set up and maintained by IMSB, University of Cologne.

Figure 1: Trial flowchart



This study is an open-label study that uses standard doses of medication. Therefore, the study drugs are not centrally distributed, repackaged, or labelled. All antimicrobial treatments are commercially available antimicrobials approved by the respective national authorities.

Depending on the susceptibility of the isolates, expected drug interactions, contraindications and expected side effects, the drug is chosen from the corresponding list below. The drugs of first choice must be administered unless allergy or intolerance is suspected or resistance of the *S. aureus* isolate has been demonstrated.

OST (oral administration)

MSSA

1st choice: Trimethoprim/sulfamethoxazole p.o.

2nd choice: Clindamycin p.o.

MRSA

1st choice: Trimethoprim/sulfamethoxazole p.o.

2nd choice: Linezolid p.o.

IST (intravenous administration)

MSSA MRSA

1st choice: Flucloxacillin i.v. 1st choice: Vancomycin i.v.

(Cloxacillin in Spain & France) or Cefazolin i.v.

2nd choice: Vancomycin i.v. 2nd choice: Daptomycin i.v.

This study compares intravenous and oral treatment regimens. Neither patients nor investigators can be fully masked regarding treatment. However, clinical response to treatment will be evaluated in a blind manner by the Clinical Review Committee (CRC), though unblinding may be requested (or may be unavoidable, e.g. when judging appropriateness of antibiotic therapy) for individual cases. Moreover, the Data Monitoring Committee (DMC) will be masked, though unblinding may be requested for individual cases.

1.3 Timing of analyses

After completion of the last visit of the last subject, when (at best) 215 subjects passed the complete trial, data will be cleaned and approved by CTCC according to their SOPs. The cleaned data will then be transferred to the statistician and the final analysis will be performed after the finalization and approval of this statistical analysis plan (SAP).

1.4 Sample size

The Scientific Advisory Committee suggested a non-inferiority margin of 10 percentage points. However, since this may be felt too large by some clinicians for the clinical question to be addressed, the study sample size was initially calculated to ensure sufficient power (i.e. 80%) even with a reduced margin of 5 percentage points (as a compromise of precision and feasibility). Both margins, i.e. 10% and 5%, are tested hierarchically in order to ensure both sufficient power and type I error control. Due to difficulties in reaching the full sample, the previously planned interim analysis at 215 patients was converted into the final analysis. This conversion accommodates a non-inferiority margin of 10% while keeping all other parameters constant (s. below).

A large prospective cohort study of 324 SAB patients indicates that patients with a removable focus of infection have a low risk (2.4%) for late complications. In a similar prospective study of 211 SAB patients with a removable focus of infection, the relapse rate with antimicrobial therapy for less than 14 days (n=134) was 3.7%. A meta-analysis of studies performed between 1967 and 1993 reported a combined rate of late complications of 6.1% in patients with catheter-related infections.

Since the in-/exclusion criteria target patients at low risk for complications, we expect a true incidence of 2.5% of late complications in study patients. This is in line with our own (INSTINCT 3%, preSABATO 1%) and other studies (2.4%, and 3.7%).

The sample size for a 10% non-inferiority margin without employing an interim analysis is calculated as follows: assuming 2.5% complications per arm, a non-inferiority margin of 10%, a one-sided alpha of 2.5% and a power of 80% requires 144 subjects in total (calculated with R version 3.3.3, package gsDesign, function nBinomial; R Foundation for Statistical Computing, Vienna, Austria), i.e. 144/0.9/0.9/0.95 = 187 subjects adjusted for deaths unrelated to SAB (10%), for protocol violations (10%) and for stratification (5%). Thus, a sample size of 215 patients does accommodate a 10% non-inferiority margin.

Observing 2.5% late complications in the final analysis (with 215*0.9*0.9*0.95/2≈83 patients per group), i.e. 0.025*83≈2 late complications in each group, yields a 90% confidence interval for the difference of -0.049 to +0.049 (Stata 15.1, StataCorp LLC, College Station, TX, USA; rdcii).

The original sample size, which included an interim analysis and a 5% non-inferiority margin, was calculated as follows: The sample size for each study arm is 165.8 (non-inferiority margin 5%, one-sided α =0.05, β =0.2, one interim analysis at information fraction 0.5 using the O'Brien-Fleming bound 2.373; calculated using ADDPLAN 6.0.1, ADDPLAN GmbH, Cologne). An allowance of 10% for deaths unrelated to SAB, of 10% for protocol violations and of 5% for stratification yields 331.6/0.9/0.9/0.95≈430 patients in total to be randomized. Note, if non-attributable mortality (i.e. about 10% within 90 days) were added to the composite endpoint, the sample size needed would approximately double (i.e. from 430 to 823 patients). Unfortunately, this cannot be achieved by the clinical network.

At the initially planned interim analysis observing 2.5% late complications, i.e. $0.025*166/2\approx2$ in each group, yields a 98.235% confidence interval (corresponds to the O'Brien-Fleming bound 2.373) for the difference of -8.2% to +8.2% (Newcombe's method 10; R. G. Newcombe, Interval estimation for the difference between independent proportions: comparison of eleven methods. Statistics in Medicine 17:873-90, 1998). At the initially planned final analysis observing 2.5% late complications, i.e. $0.025*166\approx4$ in each group, yields a 91.765% confidence interval (corresponds to the O'Brien-Fleming bound 1.678) for the difference of -3.4% to +3.4%.

2 Analysis populations

2.1 Definitions

All analyses will be done on three study populations:

The <u>primary analysis set</u> is derived from the per-protocol (PP) population. This dataset includes all study subjects who were essentially treated according to protocol and reached a defined endpoint in the trial (SAB-unrelated deaths will be excluded). The evaluability of study subjects will be assessed in a blind manner by the CRC. Details of the selection criteria and evaluation criteria are laid down in the CRC manual.

The <u>secondary analysis set</u> is derived from the intention-to-treat (ITT) population. This dataset includes all randomized study subjects, analyzed as assigned, with indeterminate and missing outcomes counted as failures. For time-to-event outcomes these cases are censored. Following current recommendations, CPMP/EWP/558/95 rev 2 and CPMP/EWP/482/99, the primary analysis is based on the per-protocol set; the analysis of the full analysis set (intention-to-treat, all randomized patients) will be of equal importance and should lead to similar conclusions for a robust interpretation.

The ITT population will be analysed as (ITT-1) any patient randomized, (ITT-2) only patients that were randomized AND received study drug without patients in whom a major inclusion criterion was violated.

The <u>tertiary analysis set</u> is for safety purposes (safety population). This dataset includes all study subjects who received any study drug as treated. Specifically, patients who ever received an oral antibiotic are compared to patients who never received an oral antibiotic.

2.2 Major protocol violations / Withdrawals

A premature withdrawal occurs when an enrolled patient ceases participation in the study prior to the completion of the protocol (e.g. withdrawn consent). All patients prematurely discontinuing from the study, regardless of cause, should receive a final evaluation at the time of withdrawal, preferably by a study visit. Premature withdrawal is considered a protocol violation and patients may be classified as non-evaluable (to be decided upon by the masked CRC). All data collected until this point of time will be stored according to AMG §40, 2a, 3. Patients will not be replaced. If possible, EOS and EOT data should be collected from each patient (this is relevant for the ITT analysis)

In case a patient is withdrawn from the study before the first dose of study drug (e.g. due to withdrawn informed consent, or a late positive follow-up blood culture), baseline information will be collected, but follow-up visits are not performed. These patients will be included in ITT-1.

3 Trial centres

1	Cologne	Prof. G.	Department I of Internal Medicine, University of Cologne
		Fätkenheuer	
2	Freiburg	Prof. W.V.	Department of Medicine, University Hospital Freiburg
		Kern	
3	Berlin	Prof. K.	Vivantes Auguste-Viktoria-Klinikum, and Vivantes
		Arastéh	Wenckebach-Klinikum, Berlin
4	Krefeld	Dr. K.	Helios Klinikum Krefeld
		Kösters	
5	Hannover	Prof. T.	Department of Respiratory Medicine, Hannover Medical
		Welte	School, Hannover

			(= · · · · · · · · · · · · · · · · · · ·
6	Jena	Prof. M. Pletz	Department of Anesthesiology and Intensive Care
			Medicine, Jena University Hospital, Jena
7	Aachen	Prof. S.	Central Unit of Hospital Infection and Hygiene,
	(closed)	Lemmen	Universitätsklinikum Aachen
8	Lübeck	Prof. J. Rupp	Medical Clinic III, University of Schleswig-Holstein,
			Lübeck
9	Leverkusen	Prof. Dr. S.	Medical Clinic 4, Klinikum Leverkusen
		Reuter	
10	Regensburg	Prof. B.	Medical Clinic I, University Hospital Regensburg
	(closed)	Salzberger	
11	Frankfurt	Prof Dr. C.	Department of Infectious Diseases, J.W. Goethe
		Stephan	University Hospital Frankfurt
12	Ulm (dropped)		Section of Infectius Diseases, Department of Medicine III, University Hospital Ulm
13	Groningen	Dr. M.	Department of Infectious Diseases, University Medical
		Wouthuyzen-	Center Groningen, NL
		Bakker	
14	Breda	Prof. J.	Amphia Hospital, Breda, NL
		Kluytmans	
15	Tilburg NI (dropped)	Prof. J.	St. Elisabeth Hospital, Tilburg
		Kluytmans	
16	Amsterdam	Prof. J.T.M.	Department of Internal Medicine and Infectious
	(dropped)	van der Meer	Diseases, Academic Medical Center, Amsterdam, NL
41	VUmc Amsterdam	Dr. K. van	Arts-microbioloog, VUmc, Afd. Medische Microbiologie
		Dijk	en Infectiepreventie, Amsterdam, NL
17	UMC Utrecht	Prof. M.	University Medical Center Utrecht, NL
		Bonten	
18	Barcelona 1	Prof. A.	Department of Infectious Diseases, Hospital Clínic of
		Soriano	Barcelona, ES
40	Utrecht	Dr. M. Vlek	Diakonessenhuis,Utrecht, NL
13	Groningen	Dr. M.	Department of Infectious Diseases, University Medical
		Wouthuyzen-	Center Groningen, NL
		Bakker	
19	Barcelona 2	Prof. B.	Hospital Universitari Vall d'Hebron, Barcelona, ES
	(dropped)	Almirante	
20	Sevilla VM	Prof. J.	Infectious Diseases Section, Hospital Universitario
		Rodríguez-	Virgen Macarena, Sevilla, ES
		Baño	
21	Sevilla VR	Prof. J.	Infectious diseases, Microbiology and Preventive
		Cisneros	Medicine Department, Hospital Universitario Virgen del
			Rocío, Sevilla, ES
	l .		

SADA	RIO	Statis	ilical Allalysis Flati (DI-03-A1, VO1)
22	Nottingham (dropped)	Prof. D. Turner	Nottingham University Hospitals NHS Trust, UK
23	Palma	Prof. M.	Seccio de Malalties Infeccioses, Hospital Universitario
		Riera	Son Espases, Palma de Mallorca, ES
24	Düsseldorf	Prof. A.	Institute of Medical Microbiology and Hospital Hygiene,
		Kaasch	University Hospital Düsseldorf
25	Annecy	Dr. J. Gaillat	Centre Hospitalier Annecy Genevois, F
26	Paris 1	Prof. E.	APHP Ambroise Paré, Paris, F
		Rouveix-	
		Nordon	
27	Paris 2	Dr. F. Mechai	APHP Avicenne, Paris, F
28	Paris 3	Prof. B.	APHP Beaujon, Paris, F
		Fantin	
29	Paris 4	Dr. R.	APHP Mondor, Paris, F
		Lepeule	
30	Paris 5	Prof. J.	APHP St. Louis, Paris, F
		Molina	
31	Chambéry	Dr. E.	CH Métropole Savoie, Chambéry, F
		Forestier	
32	La Roche sur Yon	Dr. T.	CH Départemental de Vendée, La Roche sur Yon, F
		Guimard	
33	Nantes	Prof. D.	CHU Nantes, F
		Boutoille	
34	Orléans	Dr. L.	CH Orléans, F
		Hocqeloux	
35	Quimper	Prof. J.	CH De Cournouaille, Quimper, F
		Tallarmin	
36	Rennes	Prof. P.	CHU Rennes, F
		Tattevin	
37	St. Etienne	Prof. F. Lucht	CHU St. Etienne, F
38	Grenoble	Prof. JP.	CHU Grenoble Alpes, F
		Stahl	
39	Tours	Prof. L.	CHRU Tours, F
		Bernard	

4 Analysis variables

4.1 Demography and baseline characteristics

Demography and baseline characteristics will include age, sex, weight, transfer from another hospital, prior hospitalization during one year before randomization, length of hospital stay before randomization, surgery within 30 days before randomization, immunosuppressive therapy and underlying condition (e.g. Charlson score).

4.2 Primary variable

All data will be obtained at the study visits or telephone contacts and are based on the assessment of the study physician, patient interviews, laboratory reports, and chart data. After discharge, patients are encouraged to report to the study center any changes in health (e.g. adverse events). Study site staff will follow up on reported issues.

The primary endpoint, **SAB-related complication**, defined as relapsing SAB, deep-seated infection with *S. aureus* (clinically suspected or microbiologically confirmed), or death related to SAB, will be derived from laboratory and clinical reports. Patients with either condition will be classified as "failure". To ensure a high quality of data, late complications need to be assessed by the principle investigator. SAB-related complications are classified as either "microbiologically documented" or "clinically suspected". All cases of SAB-related complication are carefully evaluated for plausibility by the masked Clinical Review Committee (CRC) on the basis of clinical symptoms, vital signs, laboratory parameters, the assessment of the study physician, patient interviews and chart data. The CRC will be provided with further information by the principle investigator as needed.

To qualify for a "microbiologically documented" relapsing SAB or deep-seated infection, the *S. aureus* isolate needs to exhibit the same characteristics as the original infecting isolate (based on antimicrobial susceptibility and genotyping tests as appropriate). Furthermore, the isolated strain needs to be judged not to represent a contaminant by the local investigator.

Relapsing SAB is defined as positive blood culture for *S. aureus* within the intervention or follow-up period. During the follow-up phase blood cultures will be taken according to standard of care at the local site, when a bloodstream infection is clinically suspected. Since every blood culture carries the risk of contamination, study sites are encouraged to draw at least two blood cultures, when clinically indicated.

Proven catheter-related *S. aureus* bloodstream infections during the follow-up period are not considered relapsing SAB, since they are highly likely to result from a new infection. Catheter-related blood-stream infection is considered "proven", when:

- The same *S. aureus* isolate is present in the positive blood culture and in the catheter tip culture, or
- The same *S. aureus* isolate is present in the positive blood culture and in pus or skin swab from the catheter exit site, or

- Two initial bloodcultures positive for *S. aureus* exhibit a positive differential time to positivity and there is no other plausible source of infection.

Deep-seated infection is any deep-seated focus of *S. aureus* infection resulting from hematogenous dissemination. In case of a microbiologically documented deep-seated infection, diagnosis requires either a positive culture from the respective site, or a blood culture positive with *S. aureus* plus imaging studies showing the presumed focus. In case of a clinically suspected deep-seated infection, microbiological results are not available or there is a plausible reason for a negative result, as finally judged by the CRC on all available evidence. Deep-seated foci consist of, but are not limited to:

- Infective endocarditis, judged by modified Duke criteria
- Vertebral and non-vertebral osteomyelitis
- Suppurative arthritis
- Spinal empyema
- Muscle abscess (e.g. psoas abscess)
- Meningitis, brain abscess
- Lung abscess
- Visceral abscess (kidney, liver, spleen, etc.)

Catheter-related infections, superficial skin-and soft tissue infections such as thrombophlebitis, or superficial wound infections do not qualify as "deep-seated", since they are likely to result from a new infection.

There is a possibility that late complications of SAB may be overlooked. By educating the patient about signs and symptoms of potential late complications, we expect that a diagnostic work-up will be performed in nearly all suspected cases. In the case of a suspected complication, the patient's current care-providers will be contacted by the principle investigator for relevant clinical information and lab reports.

In the final report detailed patient data will be listed in a table for patients that reached the primary endpoint.

4.3 Secondary variables

The **length of hospital stay** is defined as the number of days a patient spends in the hospital from date of the first positive blood culture to discharge. If the date of the first positive blood culture is prior to the date of admission to the hospital, the date of admission is used instead. When a patient is transferred to another hospital, days spent at the other hospital are included. Note: In-hospital days due to re-admissions are not counted.

Survival will be assessed during the hospital stay and at the follow-up telephone interviews. Death will be attributed to SAB when at least one of the following conditions is present:

- positive blood culture for S. aureus drawn within 72h before death
- persistent focus of deep-seated S. aureus infection at time of death

IMSB Page 12 of 19

- persistent signs and symptoms of systemic infection at time of death as judged by study physician
- post-mortem analysis proving *S. aureus* related complication as cause of death All other causes will be classified as unrelated to SAB.

The survival time is defined as the number of days a patient survives from the date of the first positive blood culture to (i) death, or (ii) end of the study, or (iii) loss of contact or withdrawal from the study.

Complications of i.v. therapy will be assessed from chart data, assessment of the study physician and from the patient interview. Complications may include, but are not limited to:

- local complications, such as: infiltration, extravasation, hematoma, phlebitis, thrombosis, thrombophlebitis, or infection at catheter insertion site
- systemic complications, such as: embolism, systemic infection, circulatory overload, allergic reaction
- in vancomycin therapy: "red man syndrome" due to inappropriately fast i.v. administration
- any other complication felt to be due to intravenous therapy by the principle investigator In patients that report diarrhea during the intervention or follow-up phase, testing for *Clostridium difficile* associated diarrhea (CDAD) is not mandatory and will be performed according to the standard of care at the respective trial site. Furthermore, AEs and SAEs are collected until EOS.

5 Handling of missing values and outliers

5.1 Missing values

Missing values will not be substituted. If subjects drop-out before end of study all data collected up until the time of subject withdrawal is to be entered into the electronic case report form (eCRF). In addition, every attempt should be made to collect follow-up information except for those subjects who specifically withdraw consent for release of such information.

For analysis of the primary endpoint the impact of missing data will be assessed in a sensitivity analysis by single/multiple imputation (based on logistic regression modelling).

For the analyses of the intention-to-treat population indeterminate and missing outcomes will be counted as failures.

5.2 Outliers

No outlier analysis will be done.

6 Statistical analyses / methods

6.1 Patient disposition

The number of patients that were screened will be counted from the screening data. The frequency of screening failures due to inclusion and exclusion criteria will be reported. Multiple selections per patient were possible.

Application of the inclusion and exclusion criteria to all included subjects will be verified.

Frequencies will be shown in a subject flow diagram. Number of and reasons for drop-outs will be included.

6.2 Demography and baseline characteristics

The first measurements (first study visit) are the baseline values. Demography and baseline characteristics (including age, sex, weight, transfer from another hospital, prior hospitalization during one year before randomization, length of hospital stay before randomization, surgery within the 30 days before randomization, immunosuppressive therapy, underlying condition, Charlson score etc.) will be summarized descriptively by treatment arm and in total for PP, ITT, and safety population. Further variables are listed in the appendix.

Descriptive statistical analyses include: number of subjects (n), arithmetic mean, standard deviation (SD), median, first quartile (Q1), third quartile (Q3), minimum (min), maximum (max) for quantitative variables and absolute and relative frequencies for qualitative variables.

6.3 Primary analysis

The primary endpoint SAB-related complications (relapsing SAB, deep-seated infection with *S. aureus*, or mortality attributable to SAB) within 90 days will be evaluated regarding non-inferiority of oral vs. intravenous antimicrobial therapy by Zhao's test (test 1) of non-null hypothesis on proportions stratified by study center at one-sided level 5% and with a non-inferiority margin of 10%. Thus, the hypotheses in terms of the proportion p of patients with SAB-related complications to be decided upon are

(A: null hypothesis) H_0 : $p_{OST} > p_{IST} + 0.10 \text{ vs}$

(A: alternative hypothesis) H_a : $p_{OST} \le p_{IST} + 0.10$

If this null hypothesis can be rejected (fixed sequence of hypotheses, thus no alpha-inflation), the above test (A) will be repeated at one-sided level 2.5%.

If this null hypothesis can also be rejected (fixed sequence of hypotheses, thus no alphainflation), the non-inferiority margin of 5% will be applied, i.e.

(B: null hypothesis) H_0 : $p_{OST} > p_{IST} + 0.05 \text{ vs}$

(B: alternative hypothesis) H_a : $p_{OST} \le p_{IST} + 0.05$

If this null hypothesis can also be rejected (fixed sequence of hypotheses, thus no alphainflation), the above test (B) will be repeated at one-sided level 2.5%.

Corresponding test-based confidence intervals will be calculated to aid interpretation.

The impact of missing data will be assessed in a sensitivity analysis by single/multiple imputation (based on logistic regression modelling).

6.4 Secondary analyses

Secondary endpoints are evaluated by descriptive methods (by treatment group), including generalised linear modelling, methods for rates, proportions and the time to event.

Time to event endpoints such as length of hospital stay or 14, 30 and 90-day survival are analysed with the Kaplan-Meier method. The log-rank test is used to compare survival curves between the two treatment groups. In addition, multivariable Cox regression models can be fitted.

The analysis of length of hospital stay is as follows: (i) Patients who died in hospital or were discharged are counted as events (no censoring); (ii) patients who died in hospital are censored, patients discharged are counted as events; (iii) patients who died in hospital are counted as events, patients discharged are censored ("reverse" Kaplan-Meier method). In addition to Kaplan-Meier curves, descriptive measures such as median and interquartile are reported, too.

Complications of intravenous therapy will be counted by treatment group and evaluated with methods for rates or proportions.

6.5 Safety

AE/SAEs will be MedDRA coded and listed / summarized by treatment group, system organ class, preferred term, severity and relationship. Further safety variables (esp. laboratory data) will be listed / summarised by treatment group using valid count and either percentage (qualitative data) or mean, standard deviation and (0, 25, 50, 75, 100) percentiles (quantitative data).

Clostridium difficile associated diarrhea (CDAD) will be counted by treatment group and analysed with methods for rates or proportions.

6.6 Subgroup analyses

Subgroup analyses (of primary and secondary endpoints) are performed by sex (male-female ratio 3:2), country (not study center since there are too many (32)) and antibiotic susceptibility status (MSSA/MRSA), respectively. Further subgroup analysis will be conducted for (1) different foci of infection, (2) patients with comorbidities (pacemaker, prosthetic joints, moderate or severe liver disease, end-stage renal failure, immune suppression (at least one of the following: corticoid therapy, neutropenia, current antineoplastic therapy, immunosuppressive therapy, organ or marrow transplant)), (3) Charlson Comorbidity Index (<3 vs. >=3), (4) performance of diagnostic echocardiography (TEE/TTE), and (5) age groups (<65y vs. >= 65y). At least 10 patients in each subgroup will be necessary for analysis. The infective focus will be grouped in "central venous catheter" (central venous catheter, Shaldon

catheter, Hickman/Broviac catheter, PICC line, and port system), "peripheral catheter" (peripheral venous catheter and arterial catheter), "skin and soft-tissue" (skin and soft tissue infection (without surgical wound) and surgical wound), "other", and "focus not identified".

6.7 Additional Analysis

Detailed data from patients that died unrelated to SAB, and are thus excluded from PP analysis, will be listed.

6.8 Interim analysis

An initially planned interim analysis will be converted into a final analysis, mainly due to difficulties in reaching the full sample size. Previously, an interim analysis was planned in the following way: A possibly adaptive interim analysis based on 215 included patients (at information fraction 0.5) serves to assess the risk-benefit ratio and may lead to (1) stopping (albeit non-mandatory) due to overwhelming non-inferiority, (2) stopping for futility/safety, (3) continuation as planned, or (4) recalculation of the sample size based on conditional power. No other adaptations will be allowed. Any adaptation of the study design suggested by the masked DMC will be based on the observed proportions of SAB-related late complications applying the inverse normal method.

7 Data problems

Not expected. If any, circumstances and treatment will be documented in the final analysis report.

8 Software

Data preparation and statistical analyses will be performed using SPSS Statistics (IBM Corp., Armonk, NY, USA) and SAS (SAS Institute Inc., Cary, NC, USA).

9 References

Clinical study protocol Uni-Koeln-1400 from 20.03.2018 (Amendment III).

10 Appendices

10.1 List of abbreviations

A discuss a sent
Adverse event
Clostridium difficile associated diarrhea
Clinical review committee
Clinical Trials Center Cologne
Deutsche Forschungsgemeinschaft
Data monitoring committee
Electronic case report form
End of treatment
Institute of Medical Statistics and Computational Biology
Intravenous standard therapy
Intention to treat
Intravenous
Maximum
Minimum
Methicillin-resistant Staphylococcus aureus
Methicillin-susceptible Staphylococcus aureus
Per os (oral)
Oral switch therapy
Per protocol
First quartile
Third quartile
Staphylococcus aureus bloodstream infection
Serious adverse event
Statistical analysis plan
Standard deviation
Standard operating procedure

10.2 List of variables for demography

1	SAB related complication within 90 days
2	Mortality
3	Death attributable to SAB
4	In hospital days
5	Days on the intensive care unit
6	Complication of i.v. therapy
7	Clostridium difficile associated diarrhea
8	Diarrhea
9	90-day mortality
10	Methicillin resistance
11	
12	Daptomycin resistance Linezolid resistance
-	
13	Clindamycin resistance
14	Cotrimoxazol resistance
15 16	Remaining days of study drug therapy
-	Intravenous drug use
17	Systemic corticosteroid therapy for >1 week
18	Neutropenia
19	Anti-neoplastic chemotherapy
20	Any other immune suppressive therapy
21	Organ or marrow transplant
22	Vascular catheter in situ at onset
23	Focus of infection established
24	Pitt Bacteremia Score
25	CRP
26	Blood pressure (systole, diastole)
27	Body temperature
28	Heart rate
29	Respiratory rate
30	History of myocardial infarction (Charlson Score)
31	Congestive heart failure (Charlson Score)
32	Peripheral vascular disease (Charlson Score)
33	Cerebrovascular disease (Charlson Score)
34	
35	Dementia (Charlson Score)
36	Liver disease (Charlson Score)
37	Renal disease (Charleen Score)
38	Chronic lung disease (Charlson Score)
39	Diabetes (Charlson Score)
40	Connective tissue disorder (Charlson Score)
41	Peptic ulcer (Charlson Score)
42	Malignancy (solid tumor) (Charlson Score)
43	Leukaemia (acute or chronic) (Charlson Score)
44	Lymphoma (Charlson Score)
45	HIV (Charlson Score)
46	Charlson Comorbidity Index

Figure 2: Analysis sets

